资讯
Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...
Investing.com - 瑞穗证券维持对市值1.78亿美元的生物技术公司Immuneering Corporation (NASDAQ:IMRX)的"跑赢大盘"评级和10.00美元的目标价，此前该公司完成了2500万美元的股权融资。根据 ...
Investing.com -- Immuneering Corp (NASDAQ:IMRX)股价周一飙升21.7%，此前这家临床阶段肿瘤公司宣布与礼来公司 (NYSE:LLY)就其第二代KRAS G12C抑制剂olomorasib达成临床供应协议。
Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...
Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...
Stocktwits on MSN16 小时
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer ...
Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...
Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...
药明康德内容团队编辑Immuneering公司今日宣布，在研疗法IMM-1-104，在正在进行的2a期临床试验中获得积极数据。截至2024年12月5日，在研疗法IMM-1-104 ...
Immuneering的主要研究项目是IMM-1-104，这是一种高选择性双MEK抑制剂，正在开发用于治疗携带RAS突变肿瘤的晚期实体瘤患者。该药物已经获得新药临床 ...
Immuneering的主要研究项目是IMM-1-104，这是一种高选择性双MEK抑制剂，正在开发用于治疗携带RAS突变肿瘤的晚期实体瘤患者。该药物已经获得新药临床 ...
InvestorsHub on MSN4 天
Immuneering Secures $25 Million in Private Placement to Advance Cancer Drug Development
Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotechnology company specializing in oncology treatments, announced ...
Immuneering的主要研究项目是IMM-1-104，这是一种高选择性双MEK抑制剂，正在开发用于治疗携带RAS突变肿瘤的晚期实体瘤患者。该药物已经获得新药临床 ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈